Clinical trials · District of Columbia
Bladder Cancer clinical trials in District of Columbia
We’re tracking 16 recruiting bladder cancer studies with a site in District of Columbia — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in District of Columbia
- NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Washington D.C., District of ColumbiaAges 40–75 - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05672615Recruiting
Mood changes during bladder cancer treatment with BCG
This study looks at how bladder cancer treatment with BCG may affect mood and emotional well-being. It may help doctors understand which patients experience mood changes during care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05649306Recruiting
Surveys for coping and sexual health in bladder cancer survivors
This study asks women with bladder cancer to complete questionnaires about how they cope emotionally and about sexual health. It may help researchers understand what support survivors need and improve survivorship care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05792722Recruiting
Testing a prostate-sparing bladder surgery for bladder cancer
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT02660645Recruiting
Blue light bladder scan for suspected bladder cancer
This trial uses a special blue-light camera during a bladder procedure to help doctors better see non-muscle-invasive bladder cancer. It may help find cancer spots more clearly so they can be treated sooner.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Washington D.C., District of ColumbiaAges 18 years+
Bladder Cancer trials by city in District of Columbia
Where these studies are running in District of Columbia
Institutions with a site for the recruiting bladder cancer studies listed above.
- Sibley Memorial Hospital · 9 studies
- MedStar Georgetown University Hospital · 5 studies
- MedStar Washington Hospital Center · 3 studies
- George Washington University Hospital · 2 studies
- Johns Hopkins Medicine
What taking part in a bladder cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Bladder Cancer trials in other states
Common questions
- Are there bladder cancer clinical trials in District of Columbia?
- Yes. We're currently tracking 16 recruiting bladder cancer studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a bladder cancer study in District of Columbia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in District of Columbia to take part?
- Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a bladder cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New bladder cancer studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.